JP2008515889A5 - - Google Patents

Download PDF

Info

Publication number
JP2008515889A5
JP2008515889A5 JP2007535700A JP2007535700A JP2008515889A5 JP 2008515889 A5 JP2008515889 A5 JP 2008515889A5 JP 2007535700 A JP2007535700 A JP 2007535700A JP 2007535700 A JP2007535700 A JP 2007535700A JP 2008515889 A5 JP2008515889 A5 JP 2008515889A5
Authority
JP
Japan
Prior art keywords
seq
xaa
conjugate molecule
cys
sabm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007535700A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008515889A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/033952 external-priority patent/WO2006041641A2/en
Publication of JP2008515889A publication Critical patent/JP2008515889A/ja
Publication of JP2008515889A5 publication Critical patent/JP2008515889A5/ja
Withdrawn legal-status Critical Current

Links

JP2007535700A 2004-10-05 2005-09-22 毒性の低下した治療剤 Withdrawn JP2008515889A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61650704P 2004-10-05 2004-10-05
US64153405P 2005-01-05 2005-01-05
PCT/US2005/033952 WO2006041641A2 (en) 2004-10-05 2005-09-22 Therapeutic agents with decreased toxicity

Publications (2)

Publication Number Publication Date
JP2008515889A JP2008515889A (ja) 2008-05-15
JP2008515889A5 true JP2008515889A5 (https=) 2008-11-13

Family

ID=36051453

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007535700A Withdrawn JP2008515889A (ja) 2004-10-05 2005-09-22 毒性の低下した治療剤

Country Status (11)

Country Link
US (2) US20060073152A1 (https=)
EP (1) EP1796718A2 (https=)
JP (1) JP2008515889A (https=)
KR (1) KR20070073886A (https=)
AU (1) AU2005294723A1 (https=)
BR (1) BRPI0516577A (https=)
CA (1) CA2583137A1 (https=)
IL (1) IL182261A0 (https=)
MX (1) MX2007003907A (https=)
RU (1) RU2007116973A (https=)
WO (1) WO2006041641A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
US8288352B2 (en) * 2004-11-12 2012-10-16 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
ES2708763T3 (es) 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
EP2176295B1 (en) 2007-07-16 2014-11-19 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
PE20090943A1 (es) 2007-07-16 2009-08-05 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
US20090035848A1 (en) * 2007-08-03 2009-02-05 Robert Hickey Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products
KR101607346B1 (ko) 2008-01-31 2016-03-29 제넨테크, 인크. 항-cd79b 항체 및 면역접합체 및 사용 방법
DK2265283T3 (da) 2008-03-18 2014-10-20 Seattle Genetics Inc Auristatin-lægemiddel-linker-konjugater
WO2010054699A1 (en) * 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
EP2513148B1 (en) 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anti-her2 antibodies and their uses
BR112013027119A8 (pt) * 2011-04-21 2018-03-06 Seattle Genetics Inc novos conjugados ligante-droga (adcs) e uso dos mesmos
EP2726881A1 (en) 2011-06-28 2014-05-07 Koninklijke Philips N.V. Means for the examination of body fluids
US20130165628A1 (en) * 2011-12-23 2013-06-27 Sri International Double Binding Constructs
WO2014210029A1 (en) * 2013-06-24 2014-12-31 Riogin Corporation Double binding constructs
BR112016004355A2 (pt) 2013-08-30 2017-10-17 Aprilbio Co Ltd constructo de fusão de parte efetora de fab anti-soroalbumina e método de preparação do mesmo
HUE049175T2 (hu) 2014-09-23 2020-09-28 Hoffmann La Roche Eljárás anti-CD79b immunkonjugátumok alkalmazására
CN111164104A (zh) 2017-08-09 2020-05-15 麻省理工学院 白蛋白结合肽缀合物及其方法
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
WO2023092733A1 (zh) * 2021-11-25 2023-06-01 苏州慧疗生物医药科技有限公司 一种用于有效递送核酸的环状多肽载体及其变化形式
CN119894936A (zh) * 2022-09-20 2025-04-25 普米斯生物技术(珠海)有限公司 抗her2抗体及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3561444A (en) * 1968-05-22 1971-02-09 Bio Logics Inc Ultrasonic drug nebulizer
US3703173A (en) * 1970-12-31 1972-11-21 Ted A Dixon Nebulizer and tent assembly
US3862925A (en) * 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US3842067A (en) * 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (https=) * 1974-03-08 1982-06-04
US4105603A (en) * 1977-03-28 1978-08-08 The Salk Institute For Biological Studies Peptides which effect release of hormones
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4635627A (en) * 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
US4624251A (en) * 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
US4970198A (en) * 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5079233A (en) * 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5606040A (en) * 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク,インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SE509359C2 (sv) * 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0611306B1 (en) * 1991-11-08 1998-07-08 Somatogen, Inc. Hemoglobins as drug delivery agents
EP0731106B1 (en) * 1993-10-01 2004-11-17 Teikoku Hormone Mfg. Co., Ltd. Dolastatin derivatives
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5780054A (en) * 1996-01-17 1998-07-14 University Of British Columbia Methods for increasing the circulation half-life of protein-based therapeutics
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US6632979B2 (en) * 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20030009395A1 (en) * 2001-07-06 2003-01-09 Yu Philip Shi-Lung Method and apparatus for providing information regarding a product
ES2411007T3 (es) * 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
EP2289942B1 (en) * 2002-04-10 2013-07-31 Genentech, Inc. Anti-HER2 antibody variants
US20050180972A1 (en) * 2002-07-31 2005-08-18 Wahl Alan F. Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
US20040032828A1 (en) * 2002-08-16 2004-02-19 Cellglide Technologies Corp. Service management in cellular networks
EP2478912B1 (en) * 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy

Similar Documents

Publication Publication Date Title
JP2008515889A5 (https=)
KR102486090B1 (ko) 생체 내 내성이 높은 항체 약물 결합체
JP2023071996A (ja) 多剤抗体薬物コンジュゲート
JP7798998B2 (ja) 抗体-alk5阻害剤コンジュゲートおよびその使用
JP2022525704A5 (https=)
RU2007116973A (ru) Терапевтические средства с пониженной токсичностью
JP2023089195A (ja) グリピカン3抗体およびそのコンジュゲート
EP4087613A1 (en) Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof
JP2023520930A (ja) 電荷多様性リンカー
HRP20200551T1 (hr) Axl-specifični konjugati protutijelo-lijek za liječenje raka
TW201709932A (zh) Cd123抗體及其共軛物
JP2015509097A5 (https=)
JP2013173792A (ja) 増強された薬理学的性質を有する活性物質を送達するための方法および組成物
KR20220052960A (ko) 표적화된 덴드리머 접합체
JP2024501894A5 (https=)
TWI845724B (zh) 用於偶聯的多肽複合物及其應用
JP2023529640A (ja) 治療用コンジュゲート
JP2024528496A (ja) ウロキナーゼ型プラスミノーゲン活性化因子受容体関連タンパク質(uparap)を標的とするヒト化抗体を含む、抗体薬物複合体
JP2026000988A (ja) Alk5阻害剤複合体およびその使用
Hui et al. An innovative site-specific anti-HER2 antibody-drug conjugate with high homogeneity and improved therapeutic index
JP2024542021A (ja) ペイロードのin vivo標的化送達用のテトラジンコンジュゲート
JP2024545170A5 (https=)
CN109414509B (zh) 使用双特异性抗体的抗体药物偶联物平台
CN114652853B (zh) 抗il-4r抗体-药物偶联物及医药用途
CN114269388A (zh) 抗体-alk5抑制剂缀合物及其用途